Further evidence of the impact of elevated Lp(a) concentration on cardiovascular outcomes and event-free survival comes from a retrospective analysis of data on 4,831 patients in the Lipid Clinic database at the Heart Institute in São Paulo, Brazil, collected between June 2006 and October 2019.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.